UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

24 Jun 2005

FDA Approves UCB's Keppra® for Use in Childhood Epilepsy

Read More
14 Jun 2005

UCB Confirms Positive Financial Outlook for 2005

Read More
13 May 2005

UCB and Lonza Enter Into a Strategic Bio-Manufacturing Alliance

Read More
19 Apr 2005

UCB Confirms Strong Quarterly Sales In The Us Xyzal Sells More Than Zyrtec In Europe

Read More
18 Apr 2005

UCB Announces European Launch Of Kentera(TM) The First European Transdermal Oxybutynin Treatment For Overactive Bladder

Read More
31 Mar 2005

First evidence of efficacy for UCB's Keppra®* in the adjunctive treatment of myoclonic seizures

Read More

Stay up-to-date on the latest news and information from UCB